BioSpace News Archive

Erin Enright and Alfonso “Chito” Zulueta Appointed to Board of Directors New Board Members Bring Skills and Experience Aligned with the Company’s Strategy,

Checkpoint Therapeutics, Inc., will present a company overview at the H.C. Wainwright Global Investment Conference, on Wednesday, May 25, 2022, at 3:00 p.m. ET.

Ryvu Therapeutics, a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced that the Company will participate in the following upcoming investors’ conferences.

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announces that it will present preclinical research supporting its planned second clinical indication, bile duct cancer, also known as cholangiocarcinoma, at the Global Embolization Oncology Symposium.

Equifund ( https://equifund.com ), a private market investment platform that delivers vetted, early-stage investment opportunities to the public, announces it successfully oversubscribed a Reg-CF offering for Kleiner Device Labs.

Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today its financial results for the quarter ending March 31, 2022, and provided an overview of recent operational highlights.

Electromed, Inc. announced the results of a third-party, clinical study presented as a clinical abstract poster at the American Thoracic Society International Conference in San Francisco, CA.

The American Cancer Society’s impact venture capital fund, BrightEdge LLC, reported $9.7 million in realized and unrealized investment gains on $18.5 million in invested capital through year-end 2021.

Dxcover Limited, a clinical stage diagnostics company developing its spectroscopic biopsy technology for early detection of multiple cancers, today announced that it will be presenting new data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 3-7.

GigaGen Inc. announced the publication of a research article titled, “Predicting antibody binders and generating synthetic antibodies using deep learning,” in the peer-reviewed journal mAbs.